Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 23,887 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 23,887 shares of Privia Health Group stock in a transaction on Friday, December 12th. The stock was sold at an average price of $25.03, for a total transaction of $597,891.61. Following the transaction, the chief financial officer directly owned 172,909 shares in the company, valued at $4,327,912.27. This represents a 12.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Privia Health Group Price Performance

Shares of PRVA stock opened at $23.81 on Wednesday. The firm has a 50-day moving average of $24.44 and a 200-day moving average of $22.81. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The company has a market cap of $2.93 billion, a P/E ratio of 183.17, a P/E/G ratio of 4.20 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings results on Tuesday, June 7th. The company reported $0.10 earnings per share for the quarter. The business had revenue of $213.61 million for the quarter. Privia Health Group had a net margin of 0.89% and a return on equity of 2.52%. As a group, research analysts expect that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PRVA has been the subject of a number of research analyst reports. Citigroup reaffirmed an “outperform” rating on shares of Privia Health Group in a research report on Friday, August 29th. Barclays upped their price objective on Privia Health Group from $22.00 to $23.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. Evercore ISI raised their target price on Privia Health Group from $28.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Canaccord Genuity Group boosted their price target on shares of Privia Health Group from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Finally, Citizens Jmp raised their price objective on shares of Privia Health Group from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Privia Health Group presently has a consensus rating of “Moderate Buy” and an average price target of $30.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in Privia Health Group by 2,852.2% in the 1st quarter. Russell Investments Group Ltd. now owns 2,657 shares of the company’s stock worth $60,000 after acquiring an additional 2,567 shares during the last quarter. CWM LLC boosted its position in Privia Health Group by 89.4% during the second quarter. CWM LLC now owns 3,416 shares of the company’s stock worth $79,000 after purchasing an additional 1,612 shares during the period. Canada Pension Plan Investment Board increased its stake in shares of Privia Health Group by 48.0% in the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after purchasing an additional 1,200 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Privia Health Group in the second quarter worth about $113,000. Finally, Covestor Ltd raised its position in shares of Privia Health Group by 39.8% in the third quarter. Covestor Ltd now owns 5,824 shares of the company’s stock valued at $145,000 after purchasing an additional 1,657 shares during the period. Institutional investors own 94.48% of the company’s stock.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.